6 days ago
3 European Growth Companies With Insider Ownership Seeing Up To 114% Earnings Growth
As European markets navigate a landscape of mixed stock index performances and ongoing trade discussions, investors are keenly observing growth opportunities within the region. In this context, companies with high insider ownership often draw attention due to their potential for alignment between management and shareholder interests, making them intriguing candidates in today's market environment.
Top 10 Growth Companies With High Insider Ownership In Europe
Name
Insider Ownership
Earnings Growth
Xbrane Biopharma (OM:XBRANE)
21.8%
56.8%
Pharma Mar (BME:PHM)
11.8%
43.3%
MedinCell (ENXTPA:MEDCL)
13.9%
130.8%
Marinomed Biotech (WBAG:MARI)
29.7%
20.2%
KebNi (OM:KEBNI B)
38.3%
94.5%
Elliptic Laboratories (OB:ELABS)
24.4%
79%
CTT Systems (OM:CTT)
17.5%
37.9%
Circus (XTRA:CA1)
24.7%
94.8%
Bonesupport Holding (OM:BONEX)
10.4%
62.3%
Bergen Carbon Solutions (OB:BCS)
12%
63.2%
Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Here's a peek at a few of the choices from the screener.
Paratus Energy Services
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Paratus Energy Services Ltd. operates through its subsidiaries to provide drilling services with a fleet of jack-up rigs under contracts in Mexico, and it has a market capitalization of NOK6.35 billion.
Operations: The company's revenue segments include $205 million from Fontis and $197.80 million from Seagems.
Insider Ownership: 30.3%
Earnings Growth Forecast: 36.5% p.a.
Paratus Energy Services has significant growth potential, with earnings forecasted to grow at 36.5% annually, outpacing the Norwegian market's 10.8%. Despite a decline in Q1 sales and net income compared to last year, the company maintains a high return on equity projection of 96.1% within three years. However, revenue growth is expected to lag behind the market at just 0.9%. The stock trades significantly below its estimated fair value but faces challenges with interest coverage from earnings.
Dive into the specifics of Paratus Energy Services here with our thorough growth forecast report.
According our valuation report, there's an indication that Paratus Energy Services' share price might be on the cheaper side.
Devyser Diagnostics
Simply Wall St Growth Rating: ★★★★★☆
Overview: Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing related to hereditary diseases, oncology, and post-transplantation monitoring across multiple regions including Europe, the Middle East, Africa, the Americas, and Asia with a market cap of approximately SEK2.52 billion.
Operations: The company's revenue is primarily derived from the sale of diagnostic kits and equipment, amounting to SEK235.10 million.
Insider Ownership: 35.4%
Earnings Growth Forecast: 115.0% p.a.
Devyser Diagnostics shows promising growth potential, with revenue projected to grow at 27.7% annually, significantly outpacing the Swedish market's 5.2%. The company recently reported a turnaround in Q2 earnings, achieving SEK 1.3 million net income compared to a loss last year. Devyser's innovative product launches in genomic blood typing and HLA loss detection bolster its research capabilities and market position. Despite low return on equity forecasts, profitability is expected within three years.
Unlock comprehensive insights into our analysis of Devyser Diagnostics stock in this growth report.
In light of our recent valuation report, it seems possible that Devyser Diagnostics is trading beyond its estimated value.
Surgical Science Sweden
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Surgical Science Sweden AB (publ) specializes in developing and marketing virtual reality simulators for evidence-based medical training globally, with a market cap of SEK8.08 billion.
Operations: The company generates revenue through two main segments: Industry/OEM, contributing SEK460.22 million, and Educational Products, accounting for SEK486.31 million.
Insider Ownership: 14.8%
Earnings Growth Forecast: 32.5% p.a.
Surgical Science Sweden demonstrates strong growth potential with earnings projected to grow 32.54% annually, outpacing the Swedish market's 16.9%. Recent Q1 results show sales of SEK 250.69 million and net income of SEK 33.24 million, reflecting positive year-over-year growth. Despite a lower profit margin than last year, insider activity remains positive with more shares bought than sold recently. The company trades at a significant discount to its estimated fair value, indicating potential investment appeal amidst board leadership changes.
Delve into the full analysis future growth report here for a deeper understanding of Surgical Science Sweden.
Our expertly prepared valuation report Surgical Science Sweden implies its share price may be too high.
Turning Ideas Into Actions
Click through to start exploring the rest of the 211 Fast Growing European Companies With High Insider Ownership now.
Ready To Venture Into Other Investment Styles? Outshine the giants: these 20 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include OB:PLSV OM:DVYSR and OM:SUS.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
